An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)

An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)

Abstract The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has been demonstrated to have comparable effectiveness or better to ATRA and chemotherapy (CHT) in non-high-risk acute promyelocytic leukemia (APL). However, the efficacy of ATRA-ATO compared to ATRA-ATO plus CHT i...

Full description

Bibliographic Details
Main Authors: Huai-Yu Wang, Sha Gong, Guo-Hui Li, Ya-Zhou Yao, Yin-Suo Zheng, Xiao-Hong Lu, Su-Hua Wei, Wei-Wei Qin, Hai-Bo Liu, Meng-Chang Wang, Jie-Ying Xi, Li-Mei Chen, Mei Zhang, Xin-Xin Zhang, Hui-Yun Zhang, Cheng-Sheng Zhang, David N. Wald, Hong-Hu Zhu, Li Liu, Peng-Cheng He
Format: Article
Language:English
Published: Nature Publishing Group 2022-11-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-022-00753-y

Internet

https://doi.org/10.1038/s41408-022-00753-y

Similar Items